DVS

Revisiting What We Missed in Landmark Epidemiological Studies

Hunting for overlooked insights in their findings and datasets with the latest AI tools

Feb 18 • 

David Van Sickle

1

May 2024

London highlights & May favorites

Plus, companies as creative acts, and promising new respiratory drugs

May 31, 2024 • 

David Van Sickle

4

4

Human curiosity as AI naturalist guide

Perplexing observations and productive holes in science

May 7, 2024 • 

David Van Sickle

4

April 2024

Healthtech vs Pulmonary Fibrosis

A quick profile of two companies working on IPF/PF

Apr 18, 2024 • 

David Van Sickle

1

Respiratory Healthtech Companies

An informal inventory of what's in the market today

Apr 3, 2024 • 

David Van Sickle

1

March 2024

Equity Prerequisite

Demands for accessible and equitable digital respiratory health are premature and counterproductive

Mar 4, 2024 • 

David Van Sickle

6

1

February 2024

Stuff making it feel like spring in February

Seriously, it is 50+ degrees here and the ice is almost gone

Feb 9, 2024 • 

David Van Sickle

2

January 2024

Digital Health vs the Causes of Incidence

We need comparative research at scale to move things forward

Jan 23, 2024 • 

David Van Sickle

4

3

December 2023

Digital health mafia departures

Making sense of company identity and individual careers

Dec 13, 2023 • 

David Van Sickle

5

November 2023

Art, technology, and health

Remembering Beatriz da Costa and PigeonBlog

Nov 22, 2023 • 

David Van Sickle

2

1

September 2023

Waterfall Charts; September favorites

People, music, writing and some legendary Excel

Sep 29, 2023 • 

David Van Sickle

3

1

When Stalled, Consider Chaos

And a recap of short summer posts on strategy

Sep 12, 2023 • 

David Van Sickle

3